Spinogenix, Inc. — SEC Form D Filing

Spinogenix, Inc. filed an SEC Form D on March 9, 2026, reporting $10.61M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
March 9, 2026
Amount reported
$10.61M
Round stage
Series A
Industry
Health Care
Website
https://spinogenix.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Spinogenix addresses the challenges posed by neurodegenerative and neuropsychiatric disorders that affect brain synapse functionality.

Solution

The company develops investigational therapeutics that aim to restore brain synapses, thereby improving cognitive and emotional symptoms in affected patients.

Why now

With increasing prevalence of neurodegenerative diseases and a growing need for effective treatments, Spinogenix offers innovative therapeutic solutions at a critical time.

Verdict

Investors backed Spinogenix primarily because of its framing as an innovative solution in an under-addressed area of neurodegenerative diseases, not merely because of the growing market for neurotherapeutics. They were implicitly betting on the unmet medical need coupled with a viable pathway to FDA approval and subsequent commercial adoption, while the limited upside arose from the overcrowded space of neurotherapeutics whereby established players dominate funding and market share.

Source: SEC EDGAR Form D filing